A new standard of care
for prostate cancer
starts with a urine sample.
The Garde Prostate Test is a non-invasive, urine-based diagnostic that gives clinicians a definitive risk assessment in 24 hours. It fits existing clinical workflows and cuts the false-positive cascade that drives most overtreatment.
The PSA test is forty-five years old. It is still the standard of care.
Three out of four positive PSA results are false alarms. The downstream consequences are real: unnecessary biopsies, MRI workups, weeks of anxiety, and treatment of cancers that would never have caused harm. This costs the healthcare system billions and leaves patients with lifelong complications.
Clinicians know the PSA is broken. It burdens patients, clinicians, and payors. No better option has replaced it.
Slow
Diagnosis takes one to two months across a chain of decision points, each relying on the results of an inaccurate test.
Indiscriminate
Nearly 70% of patients diagnosed via the existing pathway receive definitive therapy for cancers that would never have progressed.
Costly
Each diagnosis carries tens of thousands in direct cost, and treatment complications compound for years afterward.
Definitive risk stratification, from a urine sample, in 24 hours.
Where biopsy samples roughly 0.32% of the prostate, Garde captures whole-gland biology by measuring exosomal small non-coding RNA in urine. A supervised machine learning model translates the molecular signal into clinically actionable risk, aligned to existing NCCN treatment pathways and billing codes.
Start with urine
A standard, non-invasive urine sample. No biopsy, no needle, no catheter. Collected anywhere.
Extract biomarkers
Biomarkers are extracted, amplified, and quantified using established molecular biology techniques and widely-used laboratory tools.
Algorithmic analysis
A supervised ML model translates the molecular signal into a quantitative risk of clinically significant disease.
Actionable results
Test results indicate the treatment pathway that best serves the patient, aligned to NCCN treatment and billing pathways.
Better outcomes. Lower system cost. Faster answers.
Garde reduces avoidable biopsies and overtreatment by correctly identifying patients who don't need treatment, while finding aggressive disease up to a year earlier than current methods.
One platform. Many cancers. Disease-agnostic by design.
The Garde Diagnostic Platform pairs a standardized urine-to-sncRNA lab workflow with a supervised ML risk-stratification engine. Prostate cancer is our wedge, chosen for the founding team's deep domain expertise. The same workflow applies to endometrial, bladder, pancreatic, and renal indications.
Pipeline
- Prostate cancer
First indication — validation study in preparation - Endometrial cancer
Future indication - Bladder cancer
Future indication - Pancreatic cancer
Future indication - Renal cancer
Future indication
Currently raising. Let's talk.
For investor inquiries, partnership discussions, or clinical collaboration.